Colon cancer missed in simple screening test

NewsGuard 100/100 Score

A new U.S. study has revealed that a commonly used screening tool for colon cancer, sigmoidoscopy, does not pick up precancerous growths in almost two-thirds of women and the failure rate is twice as high as in men.

The researchers were surprised to find that men and women do not develop polyps in the same area of the colon.

Apparently precancerous polyps in men tend to grow in the lower portion of the colon, whereas women's polyps tend to grow deeper in the colon, beyond a flexible sigmoidoscopy's reach.

As a result of this revelation, researchers are recommending that colonoscopy, which is a more reliable but more expensive test, be considered the preferred method for most women.

Dr. Phillip Schoenfeld, of the University of Michigan Medical School, the lead researcher, says that it is known that men and women develop symptoms differently and require different approaches with other diseases such as heart attacks, and colon cancer screening should be no exception.

Sigmoidoscope exams were already in question because they find growths in only 66 percent of average-risk men, and in this new women's study, the exams did even worse, detecting growths just 35 percent of the time.

Medical guidelines recommend either procedure for those above age 50 to detect early cases of colon cancer.

The study appears in current issue of the New England Journal of Medicine.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis